Daptomycin Injectable Recalled Due to Manufacturing Deviations
Accord Healthcare is recalling Daptomycin for Injection due to manufacturing practice deviations discovered during FDA inspection. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II recall with no reported illnesses or injuries. The hazard is based on manufacturing compliance deviations rather than a documented safety event, making this a precautionary recall without evidence of actual harm.
Plain-English summary
Accord Healthcare, Inc. is recalling Daptomycin for Injection, 500 mg per vial, due to Current Good Manufacturing Practice (CGMP) deviations discovered during an FDA inspection. The product (NDC 16729-435-05) is manufactured by Intas Pharmaceuticals Limited in Ahmedabad, India, and distributed by Accord Healthcare. This is a Class II recall affecting approximately 228,760 vials.
The recalled product was distributed throughout the United States, including Puerto Rico and Canada. Multiple production batches are involved, with expiration dates ranging from September 2023 through July 2025. The affected batch numbers are R2101282, R2101600, R2200002, R2200028, R2200116, R2200142, R2200152, R2200165, R2200190, and R2201042.
CGMP deviations indicate potential quality control or manufacturing process issues that could affect product safety or effectiveness. However, no illnesses or injuries related to this product have been reported to the FDA.
Patients currently taking Daptomycin should not discontinue treatment without consulting their healthcare provider. Healthcare facilities should quarantine affected vials and contact their pharmaceutical supplier for replacement product or further instructions.
The recalled product
- Product
- DAPTOMYCIN (DAPTOMYCIN)
- Brand
- DAPTOMYCIN
- Manufacturer
- Accord Healthcare, Inc.
- Category
- Drug
- Hazard
- cgmp-deviation
- manufacturing-defect
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (15)
- Batches: R2101282
- Exp. Date 9/30/2023
- R2101600
- Exp. Date 11/30/2024
- R2200002
- R2200028
- R2200116
- R2200142
- R2200152
- Exp. Date 12/31/2024
- R2200165
- R2200190
- Exp. Date 1/31/2025
- R2201042
- Exp. Date 7/31/2025
UPCs (2)
- 0316729435055
- 316729435055
Distribution
Distribution scope not specified by the agency.
Related recalls
Same brand · DAPTOMYCIN
- ModerateDaptomycin injection recalled due to manufacturing compliance deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27